Metformina + Vildagliptina Ratiopharm

Metformin Hydrochloride, the active ingredient in Metformina + Vildagliptina Ratiopharm, is a biguanide/DPP‑4 inhibitor combination presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients when diet, exercise, and other agents are insufficient to achieve glycaemic targets.

GNH USA supplies Metformina + Vildagliptina Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina + Vildagliptina Ratiopharm is used in the treatment of disorders related to impaired glucose regulation, primarily type 2 diabetes mellitus.

- Type 2 diabetes mellitus: improves overall glycaemic control when used alone or with other antidiabetic agents. - Metabolic syndrome with hyperglycaemia: helps achieve target fasting and post‑prandial glucose levels. - Combination therapy with other antidiabetics: provides additive glucose‑lowering effect for patients inadequately controlled on monotherapy.

Metformina + Vildagliptina Ratiopharm may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhoea: frequent loose stools, usually transient. - Abdominal discomfort: cramping or pain. - Headache: mild to moderate intensity. - Dizziness: occasional light‑headedness. - Upper respiratory tract infection: mild cold‑like symptoms.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: acute inflammation of the pancreas. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Renal impairment: worsening kidney function, particularly with metformin.

Before initiating therapy, clinicians should consider several safety aspects.

- Renal function monitoring: assess eGFR before starting and periodically thereafter. - Hepatic function assessment: evaluate liver enzymes prior to treatment. - Risk of lactic acidosis: avoid in patients with severe renal or hepatic impairment. - Elderly patients: start at lower dose and monitor for accumulation. - Alcohol consumption: limit intake to reduce lactic acidosis risk. - Store at room temperature: keep in the original container, protect from moisture and heat.

Metformina + Vildagliptina Ratiopharm can interact with other medicines; some require avoidance while others need careful monitoring.

Major Interactions (Avoid): - Iodinated contrast media with metformin: may precipitate lactic acidosis in renal impairment. - Cimetidine with metformin: increases metformin plasma concentrations. - Strong CYP2C9 inhibitors with vildagliptin: raise vildagliptin exposure.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., furosemide) with metformin: can affect renal clearance. - Insulin secretagogues (e.g., sulfonylureas) with vildagliptin: heighten hypoglycaemia risk.